Pimavanserin Treatment in TS

Status Completed

Clinical Trial Summary

This research study is determining if a drug called Pimavanserin if safe and effective in the treatment of the symptoms of Tourette Syndrome. Pimavanserin is an investigational drug for Tourette Syndrome, which means it has not been approved by the United States Food and Drug Administration (FDA) to treat Tourette Syndrome. Pimavanserin has been approved by the FDA as a treatment for hallucinations in Parkinson's Disease. It is currently marketed under the name NUPLAZID (pimavanserin) capsules by Acadia Pharmaceuticals.

Clinical Trial Description

Tourette Syndrome is typically treated with drugs that block or reduce the function of dopamine (a brain chemical involved in movement). However, many of these drugs have adverse effects including irreversible, involuntary movements, typically affecting the face, known as tardive dyskinesia. Newer drugs may have lower risk of tardive dyskinesia. However, many of these drugs are still in clinical trials or are very expensive when used off-label (without FDA approval) to treat Tourette Syndrome. Given these limitations, exploring the potential of other drugs is essential in helping patients. Several studies have shown that serotonin, another chemical in the brain like dopamine, may also play a role in the symptoms of Tourette Syndrome. Serotonin is already the target of many drugs in the treatment of depression, anxiety and obsessive-compulsive disorder which frequently occur in patients with Tourette Syndrome. Pimavanserin is also a drug that works on serotonin system. This means it may be helpful in the treatment of Tourette Syndrome. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04794413
Study type	Interventional
Source	Baylor College of Medicine
Contact
Status	Completed
Phase	Early Phase 1
Start date	November 12, 2018
Completion date	February 28, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04851678` - Longitudinal Impact of Stressors in Adults With Tourette Syndrome
Completed	`NCT02605902` - Trial to Demonstrate the Efficacy and Safety of Internet-delivered Behavioral Treatment for Adults With Tic Disorders	N/A
Completed	`NCT04007913` - Incorporating teleCBIT Into a Hospital-Based Tic Program	N/A
Completed	`NCT02900144` - Modified Comprehensive Behavioral Intervention for Tics (M_CBIT)	N/A
Completed	`NCT02216474` - Brain Stimulation in Movement Disorders	N/A
Completed	`NCT02256475` - Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome	Phase 1
Completed	`NCT01329198` - Brain Stimulation for the Treatment of Tourette Syndrome	N/A
Terminated	`NCT00952601` - Pilot Study of the Modified Atkins Diet for Tourette Syndrome	Phase 1
Enrolling by invitation	`NCT00355927` - Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.	N/A
Completed	`NCT00206323` - A Randomized, Placebo-controlled, Tourette Syndrome Study.	Phase 3
Completed	`NCT00004376` - Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder	Phase 3
Completed	`NCT04498364` - Extinction Learning in Adults With Tourette Syndrome	N/A
Completed	`NCT00755339` - Role of the Sensory Experience in Generating Motor Tics in Tourette Syndrome
Completed	`NCT03325010` - Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome	Phase 2
Not yet recruiting	`NCT06081348` - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders	Phase 2
Completed	`NCT01719523` - Open-Trial of EPI-743 for Adults With Tourette Syndrome	Phase 1
Completed	`NCT01702077` - Neurofeedback for Tourette Syndrome	N/A
Completed	`NCT00231985` - Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder	Phase 2
Completed	`NCT00206336` - An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.	Phase 3
Terminated	`NCT03732534` - Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome	Phase 2